SYK · News · 20260917N

Manufacturing And Capacity

STRYKER CORP · 2026-09-17 · Importance 26 · Surprise 24

Canaccord Genuity cited ongoing manufacturing challenges in Stryker’s Peripheral Vascular unit. The report also identified unexpected seasonality in the Joint Replacement business as an operational headwind. These issues contributed to reduced analyst expectations, although the report described demand or capital activity in other segments as strong.

Key facts

• Canaccord Genuity lowered its price target for Stryker Corp. to $385 from $400 due to ongoing manufacturing challenges in its Peripheral Vascular unit and unexpected seasonality in its Joint Replacement business. source
• Analysts are revising Stryker's earnings expectations downwards amidst operational headwinds. source
• Stryker maintains strong capital demand in other segments. source
• Stryker's stock is currently trading near its 52-week low. source
• Stryker reported strong Q2 2026 results. source